Cargando…
“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488578/ https://www.ncbi.nlm.nih.gov/pubmed/31722893 http://dx.doi.org/10.1183/16000617.5022-2019 |
Ejemplares similares
-
“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
Publicado: (2019) -
“Immune mechanisms in fibrotic pulmonary sarcoidosis”. P. Weeratunga, D.R. Moller and L-P. Ho. Eur Respir Rev 2022; 31: 220178
Publicado: (2023) -
“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.
Publicado: (2015) -
“Intersections of lung progenitor cells, lung disease and lung cancer.” Carla F. Kim. Eur Respir Rev 2017; 26: 170054.
Publicado: (2017) -
“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.
Publicado: (2020)